Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Bevacizumab as first-line treatment in advanced renal cell carcinoma
2006-002851-33Phase 2Terminated
- Sponsor
- Univ. Prof. Dr. Manuela Schmidinger
- Start
- Aug 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sorafenib and bevacizumab in renal cell carcinoma (RCC), sponsored by Univ. Prof. Dr. Manuela Schmidinger. Primary endpoint: Clinical response. Started Aug 2006; status: terminated.
02
Drugs
sorafenibbevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-002851-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002851-33.